Diabetes
Diagnosis of Diabetes and the Metabolic Syndrome
Classification
FDA approves next-generation CGM with two-step insertion process
FDA approved Medtronic’s next-generation continuous glucose monitor for people with diabetes, according to an industry press release.
Large differences observed among insulin algorithms at US academic hospitals
Algorithms for initiating insulin among noncritically ill adults varied widely across 20 U.S. academic hospitals, according to a brief report published in Diabetes Technology & Therapeutics.
Spending less time in HbA1c target range may increase dementia risk for older adults
Older adults with diabetes who spend less time within their individualized HbA1c target range have a higher risk for developing Alzheimer’s disease and dementias, according to findings published in JAMA Network Open.
Patients with diabetes at time of kidney allograft loss may have lower survival
Patients who have diabetes at the time of kidney allograft loss may have a lower chance of survival compared without, according to .
Prescription fills for semaglutide dramatically increase from 2021 to 2023
The number of monthly prescription fills for semaglutide increased by 442% from 2021 to 2023, according to a research letter published in JAMA Health Forum.
GLP-1s not tied to higher risk for form of optic neuropathy that may cause blindness
Adults using a GLP-1 receptor agonist do not have increased risk for nonarteritic anterior ischemic optic neuropathy, according to data from a retrospective analysis published in Journal of Diabetes Science and Technology.
Prenatal, postpartum diabetic ketoacidosis rose for mothers with pregestational diabetes
In the U.S., diabetic ketoacidosis frequency at prenatal and delivery hospitalizations increased from 2010 to 2020 for mothers with pregestational diabetes, according to study results published in Obstetrics & Gynecology.
Angiotensin-converting enzyme inhibitors, receptor blockers may benefit patients with CKD
Patients with advanced chronic kidney disease may benefit from angiotensin-converting enzyme inhibitor and angiotensin-receptor blocker use, but the antihypertensive agents may not reduce mortality risk, a retrospective analysis shows.